1. Home
  2. VOR
  3. VOR News

Latest Vor Biopharma Inc. (VOR) News on November 29, 2025

Vor Bio assumed with a Neutral at Wedbush
VOR

TipRanks

3 days ago

Vor Bio assumed with a Neutral at Wedbush

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
VOR

Zacks

3 days ago

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
VOR

GlobeNewswire

15 days ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

VOR

MT Newswires

17 days ago

Top Midday Decliners

VOR

MT Newswires

18 days ago

Top Premarket Decliners

VOR

MT Newswires

18 days ago

Vor Biopharma Prices $100 Million Common Stock Offering; Shares Down Pre-Bell

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
VOR

GlobeNewswire

18 days ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
VOR

GlobeNewswire

18 days ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
VOR

GlobeNewswire

20 days ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences
VOR

GlobeNewswire

22 days ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
VOR

GlobeNewswire

a month ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

a month ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VOR

MT Newswires

a month ago

Vor Biopharma Says Telitacicept Sustains Efficacy in Phase 3 Myasthenia Gravis Trial in China

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
VOR

GlobeNewswire

a month ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

VOR

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 10/22/2025

VOR

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 10/20/2025

Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint
VOR

TipRanks

a month ago

Vor Bio announces Phase 3 study on telitacicept in SLE met primary endpoint

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
VOR

GlobeNewswire

a month ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
VOR

GlobeNewswire

a month ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

VOR

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 10/16/2025

VOR

MT Newswires

a month ago

Vor Biopharma Says Telitacicept Meets Primary, All Secondary Endpoints in China Late-Stage Autoimmune Disease Trial

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
VOR

GlobeNewswire

a month ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

VOR

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 10/13/2025

VOR

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 10/09/2025

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

2 months ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
VOR

GlobeNewswire

4 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

VOR

MT Newswires

5 months ago

Vor Biopharma Licenses Autoimmune Drug From RemeGen, Names New CEO

Vor Bio Announces $175 Million Private Placement
VOR

GlobeNewswire

5 months ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
VOR

GlobeNewswire

5 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)
VOR

Simply Wall St.

5 months ago

Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)

VOR

MT Newswires

7 months ago

Baird Downgrades Vor Biopharma to Neutral From Outperform

VOR

MT Newswires

7 months ago

Stifel Downgrades Vor Biopharma to Hold From Buy

VOR

MT Newswires

7 months ago

HC Wainwright Downgrades Vor Biopharma to Neutral From Buy

VOR

MT Newswires

7 months ago

Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
VOR

GlobeNewswire

7 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
VOR

Simply Wall St.

8 months ago

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
VOR

GlobeNewswire

8 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
VOR

GlobeNewswire

9 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
VOR

GlobeNewswire

10 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
VOR

Zacks

10 months ago

Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross

VOR

MT Newswires

10 months ago

Vor Biopharma Files Secondary Common Stock Shelf

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
VOR

GlobeNewswire

a year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

VOR

MT Newswires

a year ago

JMP Securities Adjusts Price Target on Vor Biopharma to $6 From $12, Keeps Market Outperform Rating

Vor Biopharma Secures $55.6M for Cancer Therapy Trials
VOR

TipRanks

a year ago

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%
VOR

GuruFocus.com

a year ago

Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

VOR

MT Newswires

a year ago

Update: Vor Biopharma Expects to Raise $55.6 Million From Private Placement; Shares Up

VOR

MT Newswires

a year ago

Wedbush Cuts Price Target on Vor Biopharma to $7 From $11, Maintains Outperform Rating

VOR

MT Newswires

a year ago

Vor Biopharma Expects to Raise $55.6 Million From Private Placement; Shares Up

Vor Bio Announces $55.6 Million Private Placement
VOR

GlobeNewswire

a year ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
VOR

GlobeNewswire

a year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio to Participate in the Stifel 2024 Healthcare Conference
VOR

GlobeNewswire

a year ago

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
VOR

GlobeNewswire

a year ago

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

VOR

MT Newswires

a year ago

Vor Biopharma Names Han Choi as Chief Financial Officer

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
VOR

GlobeNewswire

a year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

VOR

MT Newswires

a year ago

Sector Update: Health Care

VOR

MT Newswires

a year ago

Vor Biopharma Reports Positive Trem-Cell Study Data; Shares Rise

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
VOR

GlobeNewswire

a year ago

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
VOR

Simply Wall St.

a year ago

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

Vor Bio to Participate in Upcoming Investor Conferences
VOR

GlobeNewswire

a year ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
VOR

GlobeNewswire

a year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

a year ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

a year ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Italian energy company targets Britain for fleet of 20 mini-nukes
VOR

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
VOR

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North
VOR

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
VOR

Simply Wall St.

a year ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations
VOR

Simply Wall St.

a year ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
VOR

Simply Wall St.

a year ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
VOR

Simply Wall St.

a year ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled
VOR

Motley Fool

a year ago

3 Mistakes That Can Get Your Costco Membership Canceled

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

a year ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VOR

MT Newswires

2 years ago

Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
VOR

GlobeNewswire

2 years ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio to Participate in Upcoming Investor Conferences
VOR

GlobeNewswire

2 years ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

2 years ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
VOR

GlobeNewswire

2 years ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
VOR

Zacks

2 years ago

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock

Vor Bio to Participate in Upcoming Investor Conferences
VOR

GlobeNewswire

2 years ago

Vor Bio to Participate in Upcoming Investor Conferences

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
VOR

Simply Wall St.

2 years ago

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
VOR

GlobeNewswire

2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

2 years ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio to Participate in Upcoming Investor Conferences
VOR

GlobeNewswire

2 years ago

Vor Bio to Participate in Upcoming Investor Conferences

Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
VOR

Simply Wall St.

2 years ago

Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
VOR

TipRanks

2 years ago

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
VOR

GlobeNewswire

2 years ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VOR

GlobeNewswire

2 years ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BayCom Full Year 2023 Earnings: Misses Expectations
VOR

Simply Wall St.

2 years ago

BayCom Full Year 2023 Earnings: Misses Expectations

Denison Mine's (DNN) JV to Restart McClean Lake Mining Activity
VOR

Zacks

2 years ago

Denison Mine's (DNN) JV to Restart McClean Lake Mining Activity

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
VOR

Zacks

2 years ago

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

First Business Financial Services (FBIZ) Q4 Earnings Top Estimates
VOR

Zacks

2 years ago

First Business Financial Services (FBIZ) Q4 Earnings Top Estimates

BCB Bancorp (BCBP) Misses Q4 Earnings and Revenue Estimates
VOR

Zacks

2 years ago

BCB Bancorp (BCBP) Misses Q4 Earnings and Revenue Estimates

Carter Bankshares, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
VOR

ACCESSWIRE

2 years ago

Carter Bankshares, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

SEACOR Marine Announces Upgrade of Four PSVs with Kongsberg Maritime Energy Storage Systems
VOR

GlobeNewswire

2 years ago

SEACOR Marine Announces Upgrade of Four PSVs with Kongsberg Maritime Energy Storage Systems

XAI Octagon Floating Rate & Alternative Income Term Trust Announces Shareholder Approval of Important Proposals
VOR

Business Wire

2 years ago

XAI Octagon Floating Rate & Alternative Income Term Trust Announces Shareholder Approval of Important Proposals

Pleasing Signs As A Number Of Insiders Buy MVB Financial Stock
VOR

Simply Wall St.

2 years ago

Pleasing Signs As A Number Of Insiders Buy MVB Financial Stock

Director William Kussell Sells 15,000 Shares of First Watch Restaurant Group Inc (FWRG)
VOR

GuruFocus.com

2 years ago

Director William Kussell Sells 15,000 Shares of First Watch Restaurant Group Inc (FWRG)

First Watch (FWRG) Acquires Tulsa-Area Franchise Location
VOR

Zacks

2 years ago

First Watch (FWRG) Acquires Tulsa-Area Franchise Location

Southern States Bancshares, Inc. Announces Fourth Quarter 2023 Financial Results
VOR

GlobeNewswire

2 years ago

Southern States Bancshares, Inc. Announces Fourth Quarter 2023 Financial Results

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
VOR

Zacks

2 years ago

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
VOR

GlobeNewswire

2 years ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Share on Social Networks: